These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133 [TBL] [Abstract][Full Text] [Related]
23. Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia. Ibrahim S; Reeskamp LF; de Goeij JN; Hovingh GK; Planken RN; Bax WA; Min JK; Earls JP; Knaapen P; Wiegman A; Stroes ESG; Nurmohamed NS Eur J Prev Cardiol; 2024 May; 31(7):892-900. PubMed ID: 38243822 [TBL] [Abstract][Full Text] [Related]
24. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Bell DA; Hooper AJ; Bender R; McMahon J; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR Ann Clin Biochem; 2012 Nov; 49(Pt 6):534-7. PubMed ID: 23002132 [TBL] [Abstract][Full Text] [Related]
25. Genetic analysis of familial hypercholesterolaemia in Western Australia. Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Futema M; Whittall RA; Kiley A; Steel LK; Cooper JA; Badmus E; Leigh SE; Karpe F; Neil HA; ; Humphries SE Atherosclerosis; 2013 Jul; 229(1):161-8. PubMed ID: 23669246 [TBL] [Abstract][Full Text] [Related]
27. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356 [TBL] [Abstract][Full Text] [Related]
30. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Tada H; Kawashiri MA; Nohara A; Inazu A; Mabuchi H; Yamagishi M Eur Heart J; 2017 May; 38(20):1573-1579. PubMed ID: 28159968 [TBL] [Abstract][Full Text] [Related]
31. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. Mortensen MB; Kulenovic I; Klausen IC; Falk E J Clin Lipidol; 2016; 10(5):1145-1152.e1. PubMed ID: 27678431 [TBL] [Abstract][Full Text] [Related]
32. Low density lipoprotein--receptor (LDL-R) gene mutations among Filipinos with familial hypercholesterolemia. Punzalan FE; Sy RG; Santos RS; Cutiongco EM; Gosiengfiao S; Fadriguilan E; George P; Laurie A J Atheroscler Thromb; 2005; 12(5):276-83. PubMed ID: 16205024 [TBL] [Abstract][Full Text] [Related]
33. Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia. Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B J Intern Med; 2021 Aug; 290(2):404-415. PubMed ID: 33955087 [TBL] [Abstract][Full Text] [Related]
34. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Steyn K; Goldberg YP; Kotze MJ; Steyn M; Swanepoel AS; Fourie JM; Coetzee GA; Van der Westhuyzen DR Hum Genet; 1996 Oct; 98(4):479-84. PubMed ID: 8792826 [TBL] [Abstract][Full Text] [Related]
35. Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Gulizia MM; Maggioni AP; Abrignani MG; Bilato C; Mangiacapra F; Sanchez FA; Piovaccari G; Montagna L; Marini M; De Biasio M; Averna M; Casula M; Colivicchi F; Fabbri G; Lucci D; Zampoleri V; Catapano AL; Atherosclerosis; 2020 Sep; 308():32-38. PubMed ID: 32823190 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Futema M; Ramaswami U; Tichy L; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; De Leener A; Fastre E; Vrablik M; Freiberger T; Esterbauer H; Dieplinger H; Greber-Platzer S; Medeiros AM; Bourbon M; Mollaki V; Drogari E; Humphries SE Atherosclerosis; 2021 Feb; 319():108-117. PubMed ID: 33508743 [TBL] [Abstract][Full Text] [Related]
37. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. Benn M; Watts GF; Tybjaerg-Hansen A; Nordestgaard BG J Clin Endocrinol Metab; 2012 Nov; 97(11):3956-64. PubMed ID: 22893714 [TBL] [Abstract][Full Text] [Related]